Telix Medical

Hear from Telix Japan President, Shintaro Nishimura, at the 14th Joint Symposium on Cancer Drug Development taking place in Tokyo, Japan this week. Dr. Nishimura will discuss nuclear medicine diagnostic and therapeutic drug development, and how Telix has taken learnings from Australia and combined them with Japanese innovation to advance radiopharmaceutical development in Japan. For more information on the event and schedule visit: https://lnkd.in/gDs4QBS6 今週12月13日東京で開催される第14回がん新薬開発合同シンポジウム+第8回医療機器開発シンポジウムで、テリックス ジャパン株式会社代表取締役社長の西村伸太郎博士の話をお聞きください。 西村博士は核医学診断薬および治療薬の開発について、またテリックス社が創業したオーストラリアで学んだことを日本のイノベーションと組み合わせ、日本で放射性医薬品の開発をいかに進めてきたかについてお話しします。    イベントとスケジュールの詳細については、https://lnkd.in/gDs4QBS6 をご覧ください。

Published in the Journal of Nuclear Medicine, Bauckneht and colleagues report results from a restrospective analysis that support the use of 68Ga-PSMA-11 over other radiotracers for metastasis-directed therapy (MDT). The analysis included 402 patients with oligometastatic prostate cancer who underwent MDT guided by 18F-fluorocholine, 68Ga-PSMA-11, or 18F‑PSMA-1007 PET/CT. Patients who underwent 68Ga-PSMA-11 PET/CT had significantly longer progression-free survival (PFS) and time to systemic treatment change (PFS2) than those who underwent 18F-PSMA-1007 PET/CT. Patients who underwent PSMA PET/CT (regardless of PSMA radiotracer) had longer PFS and PFS2 than those who underwent 18F-fluorocholine PET/CT. https://lnkd.in/gK-_mQPS

Hear from Telix’s Director of AI Research, Simon Wail, at the 2024 Australasian Joint Conference on AI happening in Melbourne, Australia this week. Simon will discuss the role that AI and predictive analytics can play in the imaging and diagnosis of cancer and how Telix is developing solutions to support physicians in their clinical decision making. For more information on the event and schedule visit: https://lnkd.in/gEh_BmzX

Join Telix at our Satellite Symposium during the Society for Neuro-Oncology Annual Meeting 2024 taking place this week in Houston, Texas. The event will include presentations from global key opinion leaders discussing real-world experience with 18F-FET-PET (TLX101-CDx). Learning Objectives: 🧠 Recognize the limitations of conventional imaging in characterizing recurrent glioma tumors from treatment-related effects. 🧠 Demonstrate how FET-PET may help improve the characterization of recurrent glioma tumors. 🧠 Realize the value of FET-PET as a complementary imaging agent to MRI. 🧠 Understand the value of FET-PET and its appropriate use cases, in glioma, through case-studies. Don’t miss out and register today: https://lnkd.in/gb98hS6W TLX101-CDx has not received a marketing authorisation in any jurisdiction.

The first patient has been dosed at Kettering Health (OH) in a U.S. expanded access program (EAP) for TLX101-CDx (18F-floretyrosine or 18F-FET), Telix’s investigational PET agent for the characterisation of progressive or recurrent glioma - the most common and aggressive form of primary brain cancer. While TLX101-CDx is under regulatory review for U.S. marketing authorisation, the EAP facilitates continued access, where there is significant unmet medical need. U.S. patients, or physicians who may have eligible patients in the U.S. can e-mail eap-americas@telixpharma.com or complete the form here: https://bit.ly/3CA3V2J TLX101-CDx has not received a marketing authorisation in any jurisdiction

Telix is pleased to support the 2024 Head to the Hill event happening today in Canberra, Australia. The annual event aims to raise awareness about the unimproved life expectancy from brain tumours and communicate the financial, social, physical, cognitive and emotional impact to patients, families, carers and society as a whole. For more information on Brain Tumour Alliance Australia (BTAA) and the event, visit: https://lnkd.in/gEYfBNsS

Fibroblast activation protein or FAP has emerged in recent years as one of the most promising pan-cancer targets for both imaging and therapy. Here Univ.-Prof. Dr. Frederik Giesel, MD, MBA, a key opinion leader in FAP-targeted radiopharmaceuticals, speaks about the potential of the target and why it is such a ‘groundbreaking’ development in oncology. Through the recent acquisition and in-licensing of a suite of FAP-targeted compounds, Telix is positioning itself to deliver on the promise of FAP-targeted theranostics. To learn more about this target and Telix’s approach, visit our website here: https://bit.ly/48UGrkE

Join us at the Kidney Cancer Association 2024 International Kidney Cancer Symposium (IKCS) to learn more about the CA-NINE trial of Telix’s first-in-class investigational kidney cancer imaging agent, TLX250-CDx. The investigator-initiated trial, led by Prof. Brian Shuch at UCLA, will explore the diagnostic performance of this PET/CT agent in intermediate-to-high risk ccRCC post-surgery to identify the cancer where it has recurred, including metastatic disease. CA-NINE is one of multiple trials either underway or planned, which may inform future label expansion for TLX250-CDx. For the full IKCS event schedule visit: https://lnkd.in/e3Arpabs For more on the CA-NINE trial visit our website: https://lnkd.in/gNAgXKQh TLX250-CDx has not received a marketing authorisation in any jurisdiction.

For those unable to attend Telix’s sponsored symposium at EANM, we are pleased to provide a recording. Five internationally renowned key opinion leaders explored the topic of ‘Does size matter in targeted radionuclide therapies?’, sharing their perspectives on the pros and cons of different targeting agents in uro-oncology, neuro-oncology, and onco-hematology. With thanks to: Prof. Viktor Grünwald (Chair), Prof. Arturo Chiti, Prof. Nathalie Albert, Prof. Stefano Fanti and Prof. Karolien Goffin. Click here to view the full recording: https://lnkd.in/gGEtQRHe Speakers’ views are their own.

Join Telix tomorrow at the Kidney Cancer Association 2024 International Kidney Cancer Symposium (IKCS) in Louisville, Kentucky. Visit us at booth #11 to learn more about Telix’s antibody-based theranostic portfolio for kidney cancer, including TLX250-CDx, our first-in-class investigational PET agent for the non-invasive detection and characterisation of clear cell renal cell carcinoma. To learn more about the event, visit the conference website here: https://lnkd.in/e3Arpabs TLX250-CDx has not received a marketing authorisation in any jurisdiction.